Key Takeaways
Doximity Inc. (NYSE: DOCS) shares plunged 24 percent after more than 10 Wall Street firms downgraded the stock or slashed their price targets, a reaction to the company's weak fiscal 2027 forecast.
"Less visibility into growth and elevated execution risk" prompted the move, BofA Securities analyst Allen Lutz said, while keeping a buy rating but cutting his price target on the stock to $38 from $47.
The wave of revisions followed Doximity's guidance for fiscal 2027 revenue of $664 million to $676 million, implying just 3 to 5 percent growth and missing consensus estimates of $697 million. The sharpest cuts came from Jefferies, which downgraded the stock to hold from buy and cut its target to $19 from $51, and Wells Fargo, which moved to equal weight from overweight with a target cut to $18 from $32.
The sell-off has pushed Doximity's valuation down to just 8 times fiscal 2027 enterprise value to EBITDA, signaling that investors are pricing in an end to growth as the company enters a costly "AI investment year" with uncertain returns and rising competition.
The coordinated reset of expectations across the Street came after management acknowledged that spending on its DoxGPT clinical AI tool would pressure margins before generating material revenue. This spending cycle collides with new competitive threats, as KeyBanc cited the rise of "AI-driven and lower-cost alternatives" like the privately-held OpenEvidence in its downgrade.
Doximity, which operates a digital platform used by over 85 percent of U.S. physicians, generates most of its revenue from pharmaceutical advertising. Management confirmed that "short-term demand in the HCP digital pharma ad market is soft," adding another headwind to its growth outlook.
Despite the bearish sentiment, Doximity posted record free cash flow of $107 million in its most recent quarter and authorized a $500 million share repurchase program. Bulls argue the current valuation of 15 times free cash flow represents a discount for a profitable company with a dominant network, especially when compared to unprofitable peers like Hims & Hers (NYSE: HIMS). A securities law investigation by Pomerantz LLP into the company remains a risk.
The stock's recovery now depends on management demonstrating a return on its AI investments and a stabilization in the pharma ad market. The next two quarterly reports will be critical for determining if fiscal 2027 is a temporary transition or the beginning of a structural decline.
This article is for informational purposes only and does not constitute investment advice.
